Navigation Links
Hemodynamic Therapeutics Announces Successful Completion of Initial Phase 2 Clinical Study for Novel Combination Hypertension Therapy
Date:12/8/2009

DURHAM, N.C., Dec. 8 /PRNewswire/ -- Hemodynamic Therapeutics, Inc. (HTI), a portfolio company of Cato BioVentures, announces the successful completion of its initial Phase 2 clinical study of its lead compound ("HTI-101"), a patented low-dose small-molecule investigational therapy intended for patients with treatment-resistant hypertension. The 12-week double-blind placebo controlled Phase 2 study investigated the effects of a novel low dose combination of amiloride HCl and spironolactone in obese adults with treatment-resistant hypertension and statistically met its primary endpoint. HTI was assisted in the successful execution of this trial by Cato Research Ltd., a global contract research and development organization ("CRO") that is affiliated with Cato BioVentures.

"HTI remained as virtual as possible during these challenging economic times and to do this we have strategically leveraged the clinical and regulatory expertise of Cato Research in reaching this important clinical milestone for the company," said Daniel Pharand, CEO of HTI.

Obese patients were enrolled in the study with all experiencing uncontrolled hypertension while taking 3 or more anti-hypertensive medications. After only one month of treatment with HTI101, there was a significant decrease in both systolic and diastolic blood pressure.

"We are pleased to see such a strong response of HTI-101 in this important patient population and feel that this could be a new tool for treating unabated hypertension," said Allen Cato, M.D., Ph.D., CEO of Cato Research Ltd.

HTI obtained the core technology through an exclusive patent a license agreement with the University of Alabama Research Foundation ("UABRF").

About Hemodynamic Therapeutics, Inc.

HTI was formed in 2004 as a majority-owned portfolio company of Cato BioVentures. Through its strategic development relationship with Cato BioVenture
'/>"/>

SOURCE Hemodynamic Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 /PRNewswire/ - Anything Technologies Media, Inc. (OTC:EXMT) has ... Garden Solutions (FIGS), www.frontiergarden.com has been ... Project Manager for a My Compassion originated medical ... located in Alaska.  The project will be funded ... Teaming Partners. The first phase of the project, ...
(Date:7/30/2015)... 30, 2015  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... and webcast at 5:00 p.m. Eastern Time (2:00 p.m. ... second quarter 2015 financial results and provide a corporate ... NASDAQ Global Select Market closes that day. ... for domestic callers and 914.495.8552 for international callers. Please ...
(Date:7/30/2015)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) (Alimera), ... and commercialization of prescription ophthalmic pharmaceuticals, today announced that ... financial results after the market close on Monday, August ... the same day at 4:30 p.m. ET. ... Officer, and Rick Eiswirth , Chief Operating Officer ...
Breaking Medicine Technology:Frontier Indoor Garden Solutions announced as Horticultural Supplier and Project Manager for Alaskan Tribal Medical Marijuana Grow Facility 2Frontier Indoor Garden Solutions announced as Horticultural Supplier and Project Manager for Alaskan Tribal Medical Marijuana Grow Facility 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 4Alimera Sciences To Release Second Quarter Fiscal Year 2015 Financial Results 2
(Date:7/30/2015)... WASHINGTON (PRWEB) , ... July 30, 2015 , ... ... the scientific program at ATA’s 21st Annual Meeting and Tradeshow focused exclusively on ... more than 300 cutting-edge health care technology vendors, will take place May 14-17, ...
(Date:7/30/2015)... County, CA (PRWEB) , ... July 30, 2015 , ... ... County, Los Angeles, Riverside, and San Bernardino, recently announced that the Centers for Medicare ... new rating system of home health care providers. 24/7 Care At Home’s agency is ...
(Date:7/30/2015)... ... ... Ross A. Clevens, MD, FACS has been reappointed by the University ... This is Dr. Clevens’ second appointment by the prestigious school. Over the past ... and a valuable mentoring program for medical students. , The University ...
(Date:7/30/2015)... Los Angeles, California (PRWEB) , ... July 30, 2015 , ... ... of the success of the 2015 Special Olympics World Games, the largest sports and ... Angeles since the 1984 Olympic Games. , The World Games, held July 25 through ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Ocean Hills ... available, including the very rare “no recommendations.” No recommendations means CARF found no areas ... is a notation that less than 3% of all facilities receive. In addition, Ocean ...
Breaking Medicine News(10 mins):Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2
... City of Hope leads study showing efficacy of ... ... National,Marrow Donor Program (NMDP) has selected an abstract written by Dr.,Auayporn Nademanee, ... City of Hope, and Dr. Robert Chow,Founder and Global Medical Director for ...
... World Diabetes Day, November 14,is observed every year ... by others with an interest in diabetes. This year,s ... excellent opportunity,to focus on the significant increase in type ... Funded by the National Institutes of Health (NIH), researchers ...
... Percent of People with ... (Spinal Arthritis), ABBOTT PARK, Ill., Nov. 8 A ... decrease in the rate of uveitis flares by approximately half ... of the spine, and may also be associated with other ...
... Corporation,(Nasdaq: RGEN ) today reported results for the ... Total revenue for the quarter was,$5,352,000 compared to $2,865,000 ... 30, 2006, an increase of $2,487,000 or 87%. Total,revenue ... revenue.,Gross profit on product revenue for the second quarter ...
... IDMI ) today announced its financial results for ... information presented,represents the consolidated results of IDM Pharma and ... $33.2 million as of September 30,2007 compared to $37.3 ... 31, 2006. The Company,s net cash outflow from operations ...
... health diagnosis at the point-of-care and begin triage faster and easier ... ... UNION CITY, Calif., Nov. 8 Abaxis, Inc.,(Nasdaq: ABAX ), ... the U.S. Food and Drug,Administration (FDA) has granted waived status under ...
Cached Medicine News:Health News:Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From The National Marrow Donor Program 2Health News:Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From The National Marrow Donor Program 3Health News:Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From The National Marrow Donor Program 4Health News:World Diabetes Day Spotlights Type 1 Diabetes Increase and World Class Response 2Health News:World Diabetes Day Spotlights Type 1 Diabetes Increase and World Class Response 3Health News:Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab) 2Health News:Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab) 3Health News:Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab) 4Health News:Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab) 5Health News:Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab) 6Health News:Repligen Reports Second Quarter Fiscal Year 2008 Financial Results 2Health News:Repligen Reports Second Quarter Fiscal Year 2008 Financial Results 3Health News:Repligen Reports Second Quarter Fiscal Year 2008 Financial Results 4Health News:Repligen Reports Second Quarter Fiscal Year 2008 Financial Results 5Health News:Repligen Reports Second Quarter Fiscal Year 2008 Financial Results 6Health News:Repligen Reports Second Quarter Fiscal Year 2008 Financial Results 7Health News:IDM Pharma Reports Third Quarter 2007 Financial Results 2Health News:IDM Pharma Reports Third Quarter 2007 Financial Results 3Health News:IDM Pharma Reports Third Quarter 2007 Financial Results 4Health News:IDM Pharma Reports Third Quarter 2007 Financial Results 5Health News:IDM Pharma Reports Third Quarter 2007 Financial Results 6Health News:IDM Pharma Reports Third Quarter 2007 Financial Results 7Health News:IDM Pharma Reports Third Quarter 2007 Financial Results 8Health News:IDM Pharma Reports Third Quarter 2007 Financial Results 9Health News:IDM Pharma Reports Third Quarter 2007 Financial Results 10Health News:Abaxis Announces First Ever CLIA-Waived Comprehensive Metabolic Panel 2Health News:Abaxis Announces First Ever CLIA-Waived Comprehensive Metabolic Panel 3Health News:Abaxis Announces First Ever CLIA-Waived Comprehensive Metabolic Panel 4
... new Oculus Easygraph is a corneal ... tools you need for refractive surgery, ... therapy contact lens fitting in a ... 4" package. All you need to ...
The only ergonomic work station of its kind with an optional built-in keratograph and flat-screen. The Concepta is a modern workstation for the examination and refraction of patients....
The natural look of 3 in 1 technology in virtually any prescription....
Dot matrix pattern for light eyed patients....
Medicine Products: